SLC22A8 and type 2 diabetes mellitus: We present a case of severe DKA in a patient with type 2 diabetes occurring several days after co-prescription of the SGLT2 inhibitor empagliflozin alongside probenecid, an inhibitor of organic anion transporter 3 (OAT3)6, a transporter which plays a key role in the secretion of empagliflozin into the proximal tubule5.